Skip to search formSkip to main contentSkip to account menu

Evaluable Disease

Known as: Evaluable 
Disease that cannot be measured directly by the size of the tumor but can be evaluated by other methods specific to a particular clinical trial.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti‐programmed cell death‐ligand‐1 (PD‐L1) antibody, combined with gefitinib (G): A phase I expansion in TKI‐naïve…
Highly Cited
2006
Highly Cited
2006
Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.
BACKGROUND 7-Hydroxystaurosporine (UCN-01) inhibits serine-threonine kinases including the Ca2+ and phospholipid-dependent… 
Highly Cited
2000
Highly Cited
2000
Adjuvant mitozantrone chemotherapy in advanced prostate cancer
Objective To assess the role of mitozantrone, active in relapsed prostate cancer, as an adjuvant to hormonal treatment in… 
Highly Cited
1998
Highly Cited
1998
Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study.
BACKGROUND Anemia is a common side effect of anticancer chemotherapy. Blood transfusion, previously the only available treatment… 
Review
1993
Review
1993
Results of high-dose thoracic irradiation incorporating beam's eye view display in non-small cell lung cancer: a retrospective multivariate analysis.
Highly Cited
1992
Highly Cited
1992
Routine clinical on-line portal imaging followed by immediate field adjustment using a tele-controlled patient couch.
Highly Cited
1991
Highly Cited
1991
ASTRO plenary: interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: results from Radiation…
Highly Cited
1987
Highly Cited
1987
Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
Hexamethylene bisacetamide (HMBA), a potent differentiating agent, was tested in patients with refractory, solid tumors. Twenty… 
Highly Cited
1986
Highly Cited
1986
Drug and radiation sensitivity measurements of successful primary monolayer culturing of human tumor cells using cell-adhesive matrix and supplemented medium.
The limitations of the agar suspension culture method for primary culturing of human tumor cells prompted development of a… 
Highly Cited
1978
Highly Cited
1978
ABO-incompatible marrow transplants.
We analyzed data from 81 ABO-incompatible marrow transplants performed between 1972 and 1980. Patients with high anti-red blood… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)